Compare Abbott Laboratories (ABT) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Futu Holdings Ltd — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Futu Holdings Ltd trades at $95.48 (market cap $13.19B). The key difference: Abbott Laboratories is far larger — about 12.7× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| ABT | FUTU | |
|---|---|---|
Market Cap | $166.94B | $13.19B |
Sector | Health | Financials |
52-Week High | $136.62 | $199.04 |
52-Week Low | $82.57 | $89.76 |
Enterprise Value | $193.69B | $13.04B |
Dividend Yield | 2.63% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
FUTU trades at $94.03, down 1.06% on the day, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $22.85B in 2025 and a net income margin of 41.83%, but faces multiple securities class action lawsuits alleging fraud related to undisclosed regulatory penalties. Valuation ratios appear attractive with a P/E of 10.85 and EV/EBITDA of 7.16.
The outlook is clouded by legal risks and mixed earnings performance, with recent misses on EPS estimates. Analyst consensus remains positive with 58% buy ratings, but investors must weigh solid fundamentals against significant litigation overhangs and regulatory scrutiny that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
